INTRODUCTION {#sec1-1}
============

It was Cesarman and colleagues. in 1995, who first identified KSHV DNA sequences within a distinct subgroup of AIDS-related non-Hodgkin lymphomas (NHL) localized in body cavities, presenting as lymphomatous effusions.\[[@ref1]\] Subsequently, Nador *et al*. (1996) introduced the term 'primary effusion lymphoma' (PEL) in order to describe this particular type of lymphoma, which was lacking a tumor mass, but was accompanied by HHV- 8 infection.\[[@ref2]\] According to the definition provided by the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues (issue 2008), the primary effusion lymphoma is a large B-cell neoplasm that usually presents as a serous effusion without a detectable tumor mass and is universally associated with HHV-8. Some patients with PEL, secondarily develop solid tumors in the adjacent structures, such as, the pleura, whereas, rare cases of HHV-8-positive lymphomas (indistinguishable from PEL) present as solid tumor masses, and have acquired the designation of extracavitary PEL.\[[@ref3]\] Furthermore, PEL is included in the category of HIV-associated lymphomas, having been referred in the literature as 'lymphomas occurring more specifically in HIV-positive patients',\[[@ref4]\] although it has been almost simultaneously reported in HIV-negative patients also.\[[@ref5]--[@ref7]\] In this setting PEL has been linked to other immunodeficiency conditions, such as, following an organ transplantation,\[[@ref8]--[@ref10]\] cancer,\[[@ref11][@ref12]\] old age,\[[@ref13][@ref14]\] or even cirrhosis.\[[@ref15][@ref16]\] There are also published reports that describe PEL associated with liver cirrhosis and as a simultaneous infection with either Hepatitis B or C virus.\[[@ref17][@ref18]\]

As far as cytomorphology is concerned, PEL shows features bridging immunoblastic and anaplastic large-cell lymphomas, with a frequent demonstration of plasma cell differentiation. Interestingly, PEL exhibits a 'null' immunophenotype, as it lacks expression of both B- and T-cell associated antigens.\[[@ref5]\]

We herein report a case of HIV-negative PEL, with underlying Hepatitis B virus (HBV)-related liver cirrhosis, which additionally showed the relative infrequent immunocytochemical expression of T-cell associated antigens. Our case was also positive for HHV-8, a finding that along with the particular cytomorphological and immunocytochemical findings, confirmed that the lymphomatous effusion was a case of PEL.

CASE REPORT {#sec1-2}
===========

Clinical summary {#sec2-1}
----------------

The patient was an 88-year-old man of Mediterranean descent, with a history of cirrhosis and underlying HBV infection. At the time of presentation in the clinic, he complained of generalized weakness and fatigue over the last month. Physical examination revealed icterus of the skin and sclera, as well as abdominal distention, owing to the presence of ascitic fluid without any detectable hepatosplenomegaly.

The peripheral blood count showed macrocytic anemia (Hb: 11,6 g / dL, MCV: 108,0 fL), thrombocytopenia (PLT: 113 × 10^3^/ μL) and normal WBC count and differential. In particular, the exact values were as follows: WBC: 4,0 × 10^3^/ μL, Neut.: 72%, Lymph.: 18%, Mono.: 9,0%, Eosino.: 1,0%, RBC: 3,09 × 10^6^/ μL, Hb: 11,6 g / dL, MCV: 108,0 fL, MCH: 37,6 pg, and PLT: 113 × 10^3^/ μL. His serum profile provided the following results: Gluc: 105,0 mg / dl, UREA: 32,0 mg / dL, CREAT: 0,88 mg / dL, SGOT: 223,0 U / L, SGPT: 155 U / L, T-Bil.: 7,0 mg / dL, Bl-Bil.: 3,0 mg / dL, γ-GTP: 50 U / L, ALP: 165 U / L, LDH: 241 U / L, Prot: 7,4 g / dL, Alb: 2,1 g / dL, CK: 183 U / L. The biochemical examination of the collected peritoneal fluid revealed: Gluc 111 mg / dL, Prot: 2,2 g / dL, Alb: 0,65 g / dL, LDH: 1590 U / L, Chol: 7,0 mg / dL, and Trigl: 16 mg / dL.

Abdominal Ultrasound-Sonography (US) demonstrated liver cirrhosis and massive ascites. Computed-Tomography (CT), which was carried out later confirmed the ascites, although with no visible peritoneal implants. Furthermore, no pathological lymphadenopathy was detected by the obtained CT-scans.

Paracentesis was performed, yielding a large amount (800 ml) of ascitic fluid that was subsequently sent for cytological evaluation. After centrifugation of the sample, the sediment was used for ThinPrep preparation as well as for routine preparation, with direct smearing stained with both Pap and Giemsa. The remaining sediment was used for cell block preparation, using the plasma-thrombin method and standard H and E staining.

Cytological findings {#sec2-2}
--------------------

The Thin Prep material consisted of abundant large-sized malignant cells, with a moderate amount of basophilic cytoplasm, which were arranged singly. Most of them had a single nucleus, but occasionally, bi-nucleated or multinucleated cells were also seen. The nucleus had coarse chromatin pattern, irregular nuclear outlines, and a single or multiple prominent nucleoli. A high mitotic activity, with abnormal mitoses was present, and a large number of apoptotic bodies as well as nuclear debris were additionally seen \[Figures [1a](#F1){ref-type="fig"} and [1b](#F1){ref-type="fig"}\].

![(a) Cell block of FNA material showing a striking nuclear pleomorphism as well as a high mitotic index with irregular mitoses and numerous apoptotic bodies (H and E stain, magnification ×200). (b) Higher magnification of the a, with particular emphasis on the details noted above (H and E stain, magnification ×400)](CJ-9-16-g001){#F1}

Immunocytochemistry {#sec2-3}
-------------------

The immunophenotypic profile of the tumor was determined by standard immunoperoxidase methods using paraffin sections from cell block material. The primary antibodies used were: AE1 / AE3, EMA, Vimentin, Melan A, MPO, Fascin, Perforin, Bcl-6, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD30, CD34, CD43, CD45 (LCA), CD45RO, and CD138 antigens. In addition, anaplastic lymphoma kinase 1 (ALK-1) protein, TIA-1, LMP-1, and HHV-8 (Latent Nuclear Antigen-1; LANA-1) were also investigated. Antigen retrieval was performed using ethylenediamine tetraacetic acid (EDTA)-based solution (CC1). The primary antibody, secondary antibody, and avidin-enzyme conjugate were then visualized using the precipitating enzyme diaminobenzidine (DAB). The detailed immunocytochemical list of the antibodies used in our case is depicted in [Table 1](#T1){ref-type="table"}.

###### 

Immunohistochemistry-results

![](CJ-9-16-g002)

Molecular analysis {#sec2-4}
------------------

A possible Epstein--Barr virus (EBV) infection was excluded using the *EBV-encoded RNA (EBER) in situ* hybridization test in cell block material. On the contrary, the infection with he Hepatitis B virus was further confirmed with the identification of the HBV-DNA. Moreover, sediment from the ascitic fluid was examined using the polymerase chain reaction (PCR) method to detect any clonal rearrangement of the immunoglobulin heavy chain gene (IgH). Moreover, we checked for gene rearrangement in the T-cell receptor. In particular, and in more detail, the methods used are described below and the obtained results are shown in the attached figures.

Molecular analysis was performed using the IdentiClone IgH Gene Clonality Assay kit (CE-IVD, InVivoScribe Technologies, USA). The DNA was extracted and amplified by primers that target the conserved framework of the variable (V) regions, the conserved joining (J) regions, as well as the diversity and joining regions, according to the manufacturer\'s instructions. The DNA quality was tested by the Specimen Control Size Ladder Mix, which contains multiple oligonucleotides targeting the housekeeping genes \[supplied with the Kit, [Figure 3](#F3){ref-type="fig"}\].

![The performed immunocytochemistry (ICC) revealed among others, a positive reaction in the neoplastic cell population for (a) CD30 (magnification ×200), (b) CD43 (magnification ×200), (c) CD45 (magnification ×200), (d) CD45RO (magnification ×200), (e) EMA (magnification ×200), and (f) HHV-8 \[LANA-1\] (nuclear staining; magnification ×200)](CJ-9-16-g003){#F2}

![DNA quality control by Specimen Control Size ladder mix supplied with the kit. Samples at positions 1, 5, 6, 7, and 8 are controls supplied with the kit. Samples at positions 2, 3, and 4 are from patients. Sample 3 is the requested sample. Samples 2 and 4 have bad quality of DNA. M: PhiX174 / HaeIII digest ladder (New England Biolabs).](CJ-9-16-g004){#F3}

The presence or absence of clonal T-cell Receptor Gamma chain gene rearrangements was evaluated using the IdentiClone TCRG Gene Clonality Assay (CE-IVD, InVivoScribe Technologies, USA) according to the manufacturer\'s instructions, as mentioned earlier.

The PCR products were analyzed in agarose gel electrophoresis, followed by non-denaturing polyacrylamide gel electrophoresis (PAGE), in the presence of positive (clonal) and negative (polyclonal) controls \[Figures [4](#F4){ref-type="fig"}--[6](#F6){ref-type="fig"}\].

![Identification of Clonal Immunoglobulin Heavy Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gels (PAGE). Positions 1 and 8 polyclonal controls, positions 2 --4, 9 -- 11 samples, and positions 5 -- 8, 12 -- 16 clonal controls. Requested sample at positions 3 and 10.](CJ-9-16-g005){#F4}

![Identification of Clonal Immunoglobulin Heavy Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gels. Positions 1 and 9 polyclonal controls, positions 2 -- 4, 10 -- 12 samples, positions 5 -- 8, 13 -- 15 clonal controls. Requested sample at positions 3 and 11. M: PhiX174 / HaeIII digest ladder (New England Biolabs).](CJ-9-16-g006){#F5}

![Identification of Clonal T Cell Receptor Gamma Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gel (PAGE). Positions 1 and 9 polyclonal controls, positions 2 -- 5, 10 -- 13 samples, and positions 6 -- 8, 14, and 15 clonal controls. Requested sample at positions 5 and 13. M: PhiX174 / HaeIII digest ladder (New England Biolabs).](CJ-9-16-g007){#F6}

Other laboratory tests {#sec2-5}
----------------------

A bone-marrow aspirate showed no evidence of lymphoma. The serological investigation revealed the following results: HbsAg: (+), Anti-Hbc: IgG(+), Anti-Hbe: (-), HbeAg: (+), Anti-Hbs: (-), Anti-HCV: (-), and Anti-HIV: (-).

Final cytological diagnosis {#sec2-6}
---------------------------

The final diagnosis that was based on both cytological and immunocytochemical findings, in conjunction with the appropriate molecular workup, was indicative of primary effusion lymphoma with aberrant T-cell expression. The patient unfortunately died one week after the final diagnosis.

DISCUSSION {#sec1-3}
==========

Dissemination of Non-Hodgkin\'s lymphomas (NHL) in serous cavity fluids has been reported in approximately 10% of all malignant effusions.\[[@ref19]\] The term PEL was initially introduced by Nador *et al*., in 1996, in order to describe a novel type of lymphoma, presenting exclusively as a lymphomatous effusion in the absence of a detectable solid mass.\[[@ref2]\] In a majority of lymphoma cases other than PEL, a precise subtyping of the neoplasm in cytological specimens is not required, as the actual diagnosis will have been already established in the solid parts of the tumor, before the acquisition of the cytological sample.\[[@ref20]\] However, on some occasions where the serous cavity effusion is more accessible relative to the primary site of involvement, the cytological and immunocytochemical interpretation is, without doubt, of outmost importance, especially when a PEL diagnosis is under consideration.

As we have already mentioned above, primary effusion lymphoma has a strong association with HHV-8 infection, but it also seems to have a relative 'preference' for occurrence in HIV-positive individuals. Indeed, this unique type of lymphoma has been estimated to account for approximately 4% of NHL in HIV-positive patients, but only for 0.3% of NHL in HIV-negative patients.\[[@ref21]\] In these cases, where the patients are HIV negative (as in our case; see also review of all published so far \[HHV-8(+) and HIV(-)\] cases in [Table 2](#T2){ref-type="table"}), other immunodeficient conditions may exist. Our patient, although negative for HIV infection, presented with liver cirrhosis associated with Hepatitis B virus. Cirrhosis, which is an established condition of immunodeficiency,\[[@ref49]\] has been described in association with PEL; specifically there are a few reports that demonstrate the presence of PEL together with liver cirrhosis.\[[@ref15][@ref16][@ref47]\] Although a majority of PEL-cases referred to in literature are HHV-8 positive,\[[@ref34]\] there are several examples in which the absence of HHV-8, with or without a simultaneous absence of HIV infection, has been observed.\[[@ref50]--[@ref53]\] These particular cases have been further referred in the literature as 'HHV-8-unrelated PEL-like lymphomas', in order to differentiate them from 'true' PEL. Therefore, the presence of HHV-8 has been established almost as a criterion, to consider a lymphoma as a PEL, as the former is considered to play a crucial role in the pathogenesis of the latter.\[[@ref34]\] In this context, it has been proposed that the name PEL should be assigned only to this primary lymphomatous effusion that shows evidence of HHV-8 infection, along with the supportive morphological and immunophenotypical criteria.\[[@ref54][@ref55]\] The standard assay to detect HHV-8 infection in tissues is the immunocytochemical staining for LANA-1,\[[@ref56]\] whereas, EBV infection is most reliably identified by in situ hybridization for EBV-RNA, as immunocytochemical staining for EBV latent membrane protein (LMP-1) is almost always negative.\[[@ref3]\] Accordingly, after completion of the relative tests, our case has shown the presence of HHV- 8 and the absence of EBV infection. Previous molecular studies have approved the occurrence of immunoglobulin gene rearrangements (this is also true in our case) and somatic hypermutation in PEL cells, indicating that the cell of origin is a post-germinal center B-cell.\[[@ref57]\]

###### 

Table of all yet published \[HHV-8(+) and HIV(-)\] cases of PEL

![](CJ-9-16-g008)

Similarly, the experiments carried out by Fais et al., further suggested that PEL originated from mature antigen-experienced B-cells. Specifically, this group performed sequencing-analysis in immunoglobulin (*Ig*) genes from seven AIDS-related PEL. The obtained results showed that most of the samples used lambda light chain genes, two cases expressed mu chains, whereas, gamma chains were also found in two cases. In all cases, significant deviations from the presumed germline counterpart were found in both the expressed *VH* and *VL* genes. Statistical evidence for antigen selection was evident in four out of the seven samples studied. Evidence for selection was more frequent in the light chain genes than in the heavy chain genes.\[[@ref58]\] Gene expression profile analysis, which had already been performed in cases of AIDS-related PEL, had also confirmed a plasmablastic derivation.\[[@ref36]\] The cells of PEL immunocytochemically exhibited an indeterminate or 'null' lymphocyte phenotype, a they showed positive staining for the leukocyte common antigen (LCA; CD45), but negative staining for both routine B-cell- (including surface and cytoplasmic immunoglobulin, CD19, CD20, CD79a) and T-cell-markers (CD3, CD4, CD8). Instead, various markers of lymphocyte activation (CD30, CD38, CD71, human leukocyte antigen DR) and plasma cell differentiation (CD138) are usually displayed.\[[@ref54][@ref59][@ref60]\] Unlike the majority of reported cases, which show---as noted before---a 'null' immunophenotype, our case expressed, to a variable extend, T-cell markers (such as CD4, CD8, CD43; [Figure 2b](#F2){ref-type="fig"}) and CD45RO ([Figure 2d](#F2){ref-type="fig"}), but showed no expression of the B-cell marker CD20.

The occurrence of a T-cell immunophenotype in PEL is a relatively rare event and only a few cases have been published until now.\[[@ref33][@ref38][@ref47][@ref51][@ref61][@ref62]\] The differential diagnosis of PEL, on a cytomorphological ground, includes other large cell lymphomas, such as, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), with plasmacytoid differentiation, and pyothorax-associated lymphoma (PAL). Among them, the Anaplastic Large Cell Lymphoma (ALCL) and PEL share similar morphological and immunocytochemical characteristics. Morphologically, they are both high-grade lymphomas, composed of large cells with pleomorphic nuclei and prominent single-to-multiple nucleoli. However, the typical 'hallmark cells' with the eccentric kidney- or horseshoe-shaped nuclei and a prominent Golgi zone, which have been previously described in ALCL, are only seldom seen in PEL. Immunocytochemically both are positive for CD30 and EMA. Furthermore, ALCL demonstrates a T-cell immunophenotype. With regard to all the arguments raised herewith, while keeping in mind that our case also showed a T-cell profile, it was particularly difficult to rule out an ALCL. However, the negative immunostaining for ALK-1, in conjunction with the strong positivity for HHV-8, as it was a fact in our case, rendered the diagnosis of PEL as the most plausible.\[[@ref63]\] The exclusion of the rest of the lymphoma subtypes from the final diagnosis was more obvious. As far as Diffuse large B-cell lymphoma (DLBCL) and in particular the immunoblastic variant is concerned, confusion may arise, as this may also show morphological features similar to PEL. However, both the immunophenotype and HHV-8 detection are helpful in distinguishing these two entities, as DLBCL expresses B-cell markers and is HHV-8 negative. Unlike the classic Burkitt lymphoma (BL), the variant of BL with plasmacytoid differentiation, often seen in AIDS patients, may demonstrate common morphological characteristics with PEL. In these cases, immunophenotyping usually shows a B-cell lineage in BL compared with the common 'null'-phenotype of PEL or the rarer T-cell immunophenotype of our case. In addition, the negative staining for both CD10 and Bcl-6 as well as the simultaneous presence of HHV-8, all observed in the present case, did not correlate with the diagnosis of a BL.\[[@ref64]\] Finally, pyothorax-associated lymphoma (PAL) is, as the term implies, a pleural EBV-associated NHL that develops after longstanding chronic pleural inflammation. Cytologically, PAL may be indistinguishable from PEL, thus immunophenotyping and HHV-8 testing are essential in this distinction. Indeed, PAL expresses B-cell markers, is HHV-8 negative, and even more it goes hand in hand with the presence of EBV.\[[@ref64][@ref65]\]

CONCLUSION {#sec1-4}
==========

All in all, the diagnosis of PEL should be kept in mind whenever lymphomatous effusions, without a detectable primary solid mass, are present and the immunodeficiency status is either evident or is speculated. In such cases, a concrete panel of immunohistochemical markers together with specific molecular studies should be carried out. However, the hallmark of this particular entity remains the identification of HHV-8 infection.
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